Biomea Fusion, Inc. Net Change in Cash
Biomea Fusion, Inc. (BMEA) reported Net Change in Cash of -$20.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-05
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$11.12M.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$22.41M.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$31.95M.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$25.60M, a 344.29% decline year-over-year.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was -$2.47M.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$118.59M, a 282.48% decline from fiscal 2023.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $64.99M.
- Biomea Fusion, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$33.84M, a 140.10% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.99M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$11.12M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | -$2.47M 10-K · filed 2026-03-24 | |||
| 2025-09-30 | -$11.64M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | -$2.06M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | -$22.41M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$118.59M 10-K · filed 2026-03-24 | |||
| 2024-09-30 | -$88.92M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$63.58M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | -$31.95M 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $64.99M 10-K · filed 2026-03-24 | |||
| 2023-09-30 | $87.21M 10-Q · filed 2024-10-29 | |||
| 2023-06-30 | $111.01M 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | -$25.60M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | -$33.84M 10-K · filed 2025-03-31 | |||
| 2022-09-30 | -$13.43M 10-Q · filed 2023-10-30 | |||
| 2022-06-30 | $2.75M 10-Q · filed 2023-07-31 | |||
| 2022-03-31 | $10.48M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | $84.39M 10-K · filed 2024-03-28 | |||
| 2021-09-30 | $95.50M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $104.56M 10-Q · filed 2022-08-01 | |||
| 2021-03-31 | -$42.59M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $61.46M 10-K · filed 2023-03-28 | |||
| 2020-09-30 | $7.84M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $8.96M 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | -$202.00K 10-Q · filed 2021-05-27 | |||
| 2019-12-31 | $161.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |